atlantic physical therapy & chiropractic of new york, pLLC

23 bridle way
pawling, new york 12564

NYS Entity Status
ACTIVE

NYS Filing Date
MARCH 19, 2014

NYS DOS ID#
4547129

County
DUTCHESS

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC PROFESSIONAL SERVICE LIMITED LIABILITY COMPANY

Name History
2014 - ATLANTIC PHYSICAL THERAPY & CHIROPRACTIC OF NEW YORK, PLLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy VC, Deals, & Startups Feed
  • 05 October, 2016 – Episode 587 – This Week in Science Podcast (TWIS)
    By Kirsten Sanford - Thursday Oct 6, 2016

    An Interview w/ Volcanologists, 2016 Nobel Prizes, Bugs R'Us, Smart Bees, Buzzed Bees, Ancient Loot Tales, Politics Of Change, The Atlantic Conveyor, Zap And Tingle, Sideways Sharks, And Much More...

    Source: This Week in Science
  • For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY
    By Ben Fidler - Wednesday Aug 9, 2017

    A drug that actually slows or reverses the brain damage inflicted by Parkinson’s disease, rather than just alleviates its often debilitating symptoms, remains elusive. But Prevail Therapeutics, a startup just launched in New York, has become the latest to try. This morning, the Silverstein Foundation, a nonprofit organization formed by OrbiMed partner Jonathan Silverstein, announced […]

    Source: Xconomy VC, Deals, & Startups Feed
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York
  • Spark’s Gene Therapy to Restore Vision Wins Unanimous FDA Panel Vote
    By Frank Vinluan - Thursday Oct 12, 2017

    An experimental Spark Therapeutics gene therapy intended to treat rare eye diseases that lead to blindness has won the unanimous backing of an advisory panel to the FDA. Following a daylong hearing that included presentations from Philadelphia-based Spark (NASDAQ: ONCE), FDA staff, ophthalmologists, and patients, the panel of independent eye experts voted 16-0 on the […]

    Source: Xconomy VC, Deals, & Startups Feed